AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18949661 — intervention group
Group type: COMPARATOR
Intervention: Cooling jacket for 40 min
Number of subjects: 6
Study 18949661 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min water immersion followed by a cooling jacket application for 40 min
Number of subjects: 6
Study 15673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 90
Study 15673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 90
Study 15673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tramadol and morphine
Number of subjects: 90
Study 12919771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 800 mg daily
Number of subjects: 270
Study 12919771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 1600 mg daily
Number of subjects: 270
Study 12919771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 10450290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 0
Study 10450290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 0
Study 10450290 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 8582994 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortions
Number of subjects: 158
Study 8582994 — intervention group
Group type: COMPARATOR
Intervention: Obstetric controls (no induced abortions)
Number of subjects: 158
Study 8582994 — intervention group
Group type: COMPARATOR
Intervention: Non-obstetric controls (no induced abortions)
Number of subjects: 158
Study 8582994 — intervention group
Group type: EXPERIMENTAL
Intervention: Any induced abortions
Number of subjects: 158
Study 8582994 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more induced abortions
Number of subjects: 158
Study 1940606 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-mood induction condition
Number of subjects: 50
Study 1940606 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 50
Study 6261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, starting dose 60 mg daily
Number of subjects: 40
Study 6261677 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone, 10 mg/kg in rats
Number of subjects: 40
Study 31712290 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-links practitioner intervention (CLP)
Number of subjects: 288
Study 31712290 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison practices)
Number of subjects: 288
Study 29975588 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CON)
Number of subjects: 12
Study 29975588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (INT)
Number of subjects: 12
Study 27567017 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-day computerized Listening and Communication Enhancement program
Number of subjects: 263
Study 27567017 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day digital versatile disc Listening and Communication Enhancement program
Number of subjects: 263
Study 27567017 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo 'books-on-tape' training
Number of subjects: 263
Study 27567017 — intervention group
Group type: COMPARATOR
Intervention: Educational counseling (active control)
Number of subjects: 263
Study 25461963 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-light-PDT
Number of subjects: 0
Study 25461963 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL-PDT
Number of subjects: 0
Study 25461963 — intervention group
Group type: COMPARATOR
Intervention: IPL
Number of subjects: 0
Study 25461963 — intervention group
Group type: COMPARATOR
Intervention: Red-light
Number of subjects: 0
Study 23448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic powered toothbrush with unique sensing and control technologies
Number of subjects: 76
Study 23448083 — intervention group
Group type: COMPARATOR
Intervention: Manual flat-trim toothbrush
Number of subjects: 76
Study 21118875 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Edmonston‐Zagreb measles vaccine at 4.5 and 9 months of age (group A)
Number of subjects: 6648
Study 21118875 — intervention group
Group type: COMPARATOR
Intervention: One dose of Edmonston‐Zagreb measles vaccine at 9 months of age (group B)
Number of subjects: 6648
Study 21118875 — intervention group
Group type: COMPARATOR
Intervention: Schwarz measles vaccine at 9 months of age (group C)
Number of subjects: 6648
Study 18084840 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 13
Study 15076828 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone interview
Number of subjects: 278
Study 15076828 — intervention group
Group type: COMPARATOR
Intervention: Mail survey
Number of subjects: 278
Study 11432684 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs
Number of subjects: 18585
Study 11432684 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 18585
Study 11432684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18585
Study 11432684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine-treated groups
Number of subjects: 18585
Study 9129531 — intervention group
Group type: EXPERIMENTAL
Intervention: EchiTab (one vial, 10 ml; 0.5 g protein)
Number of subjects: 7
Study 9129531 — intervention group
Group type: COMPARATOR
Intervention: Institute Pasteur Serum (Ipser) Africa antivenom (four ampules, 40 ml; 2.12 g protein)
Number of subjects: 7
Study 8176008 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic evaluation by six dermatopathologists
Number of subjects: 149
Study 8176008 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic dysplasia correlation with nevus size
Number of subjects: 149
Study 8176008 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of different diagnostic criteria for histologic dysplasia
Number of subjects: 149
Study 3286518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg/b.i.d.)
Number of subjects: 30
Study 3286518 — intervention group
Group type: COMPARATOR
Intervention: Cefalexin (1 g/t.i.d.)
Number of subjects: 30
Study 3286518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefalexin-resistant bacterial strains (open study arm)
Number of subjects: 30
Study 30219032 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and Cognitive Training (PTCT)
Number of subjects: 100
Study 30219032 — intervention group
Group type: COMPARATOR
Intervention: Physical Training (PT)
Number of subjects: 100
Study 27321604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise group (n = 35) - two strength and two walking sessions
Number of subjects: 105
Study 27321604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n = 35) - four walking sessions
Number of subjects: 105
Study 27321604 — intervention group
Group type: COMPARATOR
Intervention: Social control group (n = 35) - four nonexercise social visits per week
Number of subjects: 105
Study 25381300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Number of subjects: 17
Study 25381300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22541738 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + olive oil
Number of subjects: 785
Study 22541738 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 785
Study 22541738 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 785
Study 20639624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (BPs) treatment
Number of subjects: 0
Study 17850560 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 35
Study 17850560 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 35
Study 16212851 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 154
Study 16212851 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Disorder Guidelines
Number of subjects: 154
Study 16212851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 154
Study 16212851 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 154
Study 12372131 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 200 microg/day (constant dose group)
Number of subjects: 55
Study 12372131 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 1000 microg/day with reductions to 500, 200 and 100 microg/day (stepdown group)
Number of subjects: 55
Study 10669910 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) with 300 mg of phenytoin (DPH)
Number of subjects: 20
Study 10669910 — intervention group
Group type: COMPARATOR
Intervention: Water with 300 mg of phenytoin (DPH)
Number of subjects: 20
Study 8960728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon beta-1b (8.0 million units)
Number of subjects: 30
Study 8960728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon beta-1b (1.6 million units)
Number of subjects: 30
Study 8960728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2012909 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-hospital treatment
Number of subjects: 86
Study 2012909 — intervention group
Group type: COMPARATOR
Intervention: In-patient care
Number of subjects: 86
Study 7044656 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted improved therapy (A group)
Number of subjects: 74
Study 7044656 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (U group)
Number of subjects: 74
Study 30476269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive sleep restriction condition
Number of subjects: 21
Study 30476269 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep (R2)
Number of subjects: 21
Study 30476269 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep (R2 and R3)
Number of subjects: 21
Study 30476269 — intervention group
Group type: COMPARATOR
Intervention: Baseline sleep
Number of subjects: 21
Study 29183574 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-1β (reIL-1β)
Number of subjects: 0
Study 29183574 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical biopsy technique
Number of subjects: 0
Study 29183574 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique
Number of subjects: 0
Study 26374297 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRP)
Number of subjects: 27
Study 26374297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25401325 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 100 mg/d
Number of subjects: 14464
Study 25401325 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 14464
Study 22833639 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole tablet 200 mg once daily
Number of subjects: 24
Study 22833639 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole tablet 200 mg twice daily
Number of subjects: 24
Study 22833639 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole tablet 400 mg once daily
Number of subjects: 24
Study 22833639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19110026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 43
Study 19110026 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 43
Study 19110026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 43
Study 17767075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (10,000 KIU test dose, 2 million KIU load, 0.5 million KIU per hour)
Number of subjects: 393
Study 17767075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 17767075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 393
Study 15164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical meniscus tests with high specificity and low sensitivity
Number of subjects: 64
Study 15164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical meniscus tests with high sensitivity and low specificity
Number of subjects: 64
Study 15164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of different tests
Number of subjects: 64
Study 12053271 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of toxoplasma encephalitis
Number of subjects: 0
Study 12053271 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of primary central nervous system lymphoma
Number of subjects: 0
Study 12053271 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of cryptococcal meningitis
Number of subjects: 0
Study 12053271 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of cytomegalovirus encephalitis
Number of subjects: 0
Study 12053271 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of progressive multifocal leukoencephalopathy
Number of subjects: 0
Study 9696955 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg. 1(‐1) and 9 mg. 1(‐1))
Number of subjects: 10
Study 9696955 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (3 mg. 1(‐1), 6 mg. 1(‐1), and 12 mg. 1(‐1))
Number of subjects: 10
Study 9696955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9696955 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and Theophylline (all doses)
Number of subjects: 10
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) at a dose of 72 mg/body
Number of subjects: 415
Study 7511070 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADR) at a dose of 48 mg/body
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR) in low-risk category
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) in low-risk category
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR) in high-risk category
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) in high-risk category
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum alpha-fetoprotein level
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of Lipiodol accumulation in the tumor
Number of subjects: 415
Study 7511070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of tumor reduction
Number of subjects: 415
Study 3947524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 8 litres/min
Number of subjects: 10
Study 3947524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 6 litres/min
Number of subjects: 10
Study 3947524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 4 litres/min
Number of subjects: 10
Study 29114907 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg) intravenous infusion at day 0 and at 12 months
Number of subjects: 306
Study 27296360 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 57
Study 27296360 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 24862906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 983
Study 24862906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in nonischemic cardiomyopathy
Number of subjects: 983
Study 24862906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in ischemic patients
Number of subjects: 983
Study 24862906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in nonischemic patients
Number of subjects: 983
Study 22347699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous counselling and medical advice in the intervention group
Number of subjects: 39
Study 22347699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 20302588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Number of subjects: 227
Study 20302588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Number of subjects: 227
Study 20302588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week quadruple therapy
Number of subjects: 227
Study 20302588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week quadruple therapy
Number of subjects: 227
Study 18380529 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 28
Study 18380529 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28
Study 18506347 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 61
Study 18506347 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted suture technique
Number of subjects: 61
Study 18506347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the interrupted suture group)
Number of subjects: 61
Study 15715813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 0
Study 15715813 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 11072058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness of movement intervention (six individual one-to-one sessions, audio and videotape aides)
Number of subjects: 8
Study 11072058 — intervention group
Group type: COMPARATOR
Intervention: Control group (current care)
Number of subjects: 8
Study 11072058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness of movement intervention
Number of subjects: 8
Study 9411543 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 116
Study 9411543 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 116
Study 9411543 — intervention group
Group type: COMPARATOR
Intervention: Drug-free regimen
Number of subjects: 116
Study 9411543 — intervention group
Group type: COMPARATOR
Intervention: Liver necrosis index (for drug-free regimen)
Number of subjects: 116
Study 9411543 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 116
Study 8416022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 8
Study 8416022 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 3305334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tar cigarette
Number of subjects: 183
Study 3305334 — intervention group
Group type: COMPARATOR
Intervention: Middle-tar cigarette
Number of subjects: 183
Study 30958831 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBSCT‐BA (Cognitive-behavioral smoking cessation treatment with behavioral activation)
Number of subjects: 275
Study 30958831 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBSCT (Standard cognitive-behavioral treatment)
Number of subjects: 275
Study 30958831 — intervention group
Group type: COMPARATOR
Intervention: SCBSCT‐BA
Number of subjects: 275
Study 30958831 — intervention group
Group type: COMPARATOR
Intervention: Both active groups (SCBSCT‐BA and SCBSCT)
Number of subjects: 275
Study 30958831 — intervention group
Group type: COMPARATOR
Intervention: Participants who quit smoking
Number of subjects: 275
Study 30256095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water treatment, sanitation, handwashing (WSH)
Number of subjects: 0
Study 30256095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 27325795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/day
Number of subjects: 50
Study 27325795 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D 400 IU/day
Number of subjects: 50
Study 25294886 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX ± cetuximab therapy
Number of subjects: 1657
Study 22083298 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM device activated
Number of subjects: 21
Study 22083298 — intervention group
Group type: COMPARATOR
Intervention: CCM device deactivated
Number of subjects: 21
Study 22083298 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM device activated under dobutamine stress
Number of subjects: 21
Study 22083298 — intervention group
Group type: COMPARATOR
Intervention: CCM device deactivated under dobutamine stress
Number of subjects: 21
Study 19606688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of gallbladder contractility after standard fatty meal stimulation
Number of subjects: 113
Study 19606688 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 113
Study 19606688 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound evaluation after successful treatment of basic diseases
Number of subjects: 113
Study 17826777 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels measured prior to viewing sexual stimuli
Number of subjects: 15
Study 15118191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen depletion protocol followed by 15-min downhill run (DEP group)
Number of subjects: 33
Study 15118191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen depletion protocol followed by carbohydrate repletion protocol (>80% CHO) prior to downhill running (FED group)
Number of subjects: 33
Study 15118191 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min downhill running protocol only (ECC group)
Number of subjects: 33
Study 15118191 — intervention group
Group type: COMPARATOR
Intervention: All groups (DEP, FED, ECC)
Number of subjects: 33